Diagnostics solution provider Qiagen said it will expand its business in the Middle East region with regional headquarters in Riyadh, Saudi Arabia, on Wednesday, with an aim to improve its ability to serve clients in the area.
The company said the expansion is also to accommodate its growing regional presence and customer needs, Qiagen will further strengthen its commitment to the Middle East.
Simona Grandits, head of Sales and Marketing at QIAGEN stated, “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.”
The company recently signed an MoU with the Ministry of Health of Saudi Arabia that covers various public health and infection control initiatives and aligns with the Health Sector Transformation Program of Saudi Arabia’s Vision 2030, Qiagen added.
The US-based company said through its partnership with Taiba Medserv, pharmaceutical manufacturer, will provide QuantiFERON-TB Gold Plus assays to Oman’s new program, with an objective to test for latent tuberculosis in expatriates applying for residency in the Gulf state starting in early 2024.
Qiagen is a biotech firm that prepares samples as the first essential step of any molecular analysis, one that is key in the world of diagnostics and fundamental research.
To read more on Technology, head to the link.
